BUZZ-杰富瑞将 Nurix Therapeutics 评为 "买入"，并设定最高市盈率

Reuters10-11

((自动化翻译由路透提供，请见免责声明 ))

10月11日 - ** 杰富瑞（Jefferies）对药物开发商Nurix Therapeutics 的评级为 "买入"，目标价为41美元，这是华尔街的最高价。

** 杰富瑞的 "买入 "评级是该股自7月以来的首个看涨评级--LSEG

** 券商的PT较该股上次收盘价上涨约88%。

** 该公司用于治疗癌症和炎症疾病的蛋白质调节药物的早期数据前景看好，在2025年具有 "举足轻重的潜力"--杰富瑞

** 券商预计该药物调整后的峰值销售额约为 28 亿美元

** 跟踪 NRIX 的 13 位分析师的平均评级为 "买入"；中位数 PT 为 30 美元

** 截至上次收盘，股价已上涨一倍多

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2474066421?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-10-11 18:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2474066421","market":"us","top_or_hot":-1,"title":"BUZZ-杰富瑞将 Nurix Therapeutics 评为 \"买入\"，并设定最高市盈率","media":"Reuters","content":"<html><body><p>((自动化翻译由路透提供，请见免责声明 ))</p><p>    10月11日 - ** <a href=\"https://laohu8.com/S/JEF\">杰富瑞</a>（Jefferies）对药物开发商<a href=\"https://laohu8.com/S/NRIX\">Nurix Therapeutics</a>   的评级为 \"买入\"，目标价为41美元，这是华尔街的最高价。</p><p>** 杰富瑞的 \"买入 \"评级是该股自7月以来的首个看涨评级--LSEG</p><p>** 券商的PT较该股上次收盘价上涨约88%。</p><p>** 该公司用于治疗癌症和炎症疾病的蛋白质调节药物的早期数据前景看好，在2025年具有 \"举足轻重的潜力\"--杰富瑞</p><p>** 券商预计该药物调整后的峰值销售额约为 28 亿美元</p><p>** 跟踪 NRIX 的 13 位分析师的平均评级为 \"买入\"；中位数 PT 为 30 美元</p><p>** 截至上次收盘，股价已上涨一倍多 </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-杰富瑞将 Nurix Therapeutics 评为 \"买入\"，并设定最高市盈率</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-杰富瑞将 Nurix Therapeutics 评为 \"买入\"，并设定最高市盈率\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-11 18:12 北京时间&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>((自动化翻译由路透提供，请见免责声明 ))    10月11日 - ** 杰富瑞（Jefferies）对药物开发商Nurix Therapeutics   的评级为 \"买入\"，目标价为41美元，这是华尔街的最高价。** 杰富瑞的 \"买入 \"评级是该股自7月以来的首个看涨评级--LSEG** 券商的PT较该股上次收盘价上涨约88%。** 该公司用于治疗癌症和炎症疾病的蛋白质调节药物的早期数据前景...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LENZ","symbol_name":"Therapeutics","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2474066421","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2474066421","pubTimestamp":1728641530,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"    10月11日 - ** 杰富瑞对药物开发商Nurix Therapeutics   的评级为 \"买入\"，目标价为41美元，这是华尔街的最高价。** 杰富瑞的 \"买入 \"评级是该股自7月以来的首个看涨评级--LSEG** 券商的PT较该股上次收盘价上涨约88%。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LENZ":"Therapeutics","BK4127":"投资银行业与经纪业","JEF":"杰富瑞","BK4139":"生物科技","NRIX":"Nurix Therapeutics"},"translate_title":"BUZZ-Jefferies rates Nurix Therapeutics a \"Buy\" and sets top P/E","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JEF":1,"LENZ":1,"NRIX":1},"content_text":"((自动化翻译由路透提供，请见免责声明 ))    10月11日 - ** 杰富瑞（Jefferies）对药物开发商Nurix Therapeutics   的评级为 \"买入\"，目标价为41美元，这是华尔街的最高价。** 杰富瑞的 \"买入 \"评级是该股自7月以来的首个看涨评级--LSEG** 券商的PT较该股上次收盘价上涨约88%。** 该公司用于治疗癌症和炎症疾病的蛋白质调节药物的早期数据前景看好，在2025年具有 \"举足轻重的潜力\"--杰富瑞** 券商预计该药物调整后的峰值销售额约为 28 亿美元** 跟踪 NRIX 的 13 位分析师的平均评级为 \"买入\"；中位数 PT 为 30 美元** 截至上次收盘，股价已上涨一倍多","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2474066421"}